Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 13/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907138 | 0.87 | ADORA1 (0.58) | ADORA1ADORA2AADORA2BMAPTNPSR1 | |
| SCHEMBL4904033 | 0.81 | ADORA1 (0.77) | ADORA1ADORA2AADORA2BMAPTNPSR1 | |
| SCHEMBL4909492 | 0.81 | MAPT (0.51) | ADORA1ADORA2AADORA2BMAPTRXFP1 | |
| SCHEMBL27631464 | 0.76 | IGF1R (0.56) | ADORA2AMAPTNPSR1IGF1RBACE1 | |
| SCHEMBL6446566 | 0.76 | ADORA1 (0.63) | ADORA1ADORA2AADORA2BSQOR | |
| SCHEMBL978442 | 0.72 | IGF1R (0.57) | ADORA1ADORA2AMAPTNPSR1IGF1R | |
| SCHEMBL14413783 | 0.72 | ADORA1 (0.65) | ADORA1ADORA2AADORA2BMAPTRXFP1 | |
| SCHEMBL1877640 | 0.71 | BACE1 (0.49) | ADORA1ADORA2AADORA2BNPSR1IGF1R | |
| SCHEMBL18005947 | 0.71 | NAAA (0.47) | IGF1RMAOB | |
| SCHEMBL1171578 | 0.70 | GABRG2 (0.66) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984377-A2 | INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | Signal Pharmaceuticals LLC (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | MCKENNA JEFFREY M | 2008-01-03 | — | — | US | disclosed |
| WO-2007084560-A2 | INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004271-A1 | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith | PDE4A, PDE4B, BRAF | ADORA1 529/4885ADORA2A 837/4885ADORA2B 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.